Halozyme Therapeutics, Inc. Q3 2025 results
Snapshot
Halozyme Therapeutics, Inc. reported $354M of revenue in Q3 2025, up 22.1% year over year, with diluted EPS of $1.43 and an operating margin of 61.5%.
- Revenue
- $354M
- YoY growth
- +22.1%
- Diluted EPS
- $1.43
- Operating margin
- 61.5%
What management said
- •Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business, and Nicole LaBrosse, our Chief Financial Officer, will review our financial results as well as our outlook.
- •Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.
- •I am very pleased to report another quarter of record royalty revenue of $236 million, representing a remarkable 52% increase year-over-year, and resulting in total revenue of $354 million, representing 22% growth year-over-year.
- •Adjusted EBITDA growth exceeded top-line growth, increasing 35% over prior year's third quarter to $248 million, reflecting the strength inherent in our royalty-based business model.
- •Year to date, 13 of the 15 growth catalysts have been achieved, including new product approvals, expanded indications, reaching new regions, and achieving key reimbursement milestones across major markets.
- •This quarter, there were two notable indication approvals for our two leading growth drivers.
- •Firstly, Darzalex Subcutaneous received European Commission approval for a new indication in smoldering multiple myeloma, providing another meaningful growth catalyst for the franchise.
- •Driven by the continued strong performance of our core ENHANZE technology, we are pleased to raise our full year 2025 guidance ranges.
- •Driven by royalty revenues, we now project total revenue of $1.3 billion-$1.375 billion, reflecting 28%-35% growth over 2024.
- •Royalty revenue is now expected to grow 49%-54% to $850 million-$880 million for the full year, primarily driven by our three established blockbuster subcutaneous therapies, Darzalex Subcutaneous, Phesgo, and VYVGART Hytrulo with ENHANZE.
- •We now anticipate adjusted EBITDA of between $885 million and $935 million, representing year-over-year growth of 40%-48%.
- •We expect non-GAAP diluted earnings per share of $6.10-$6.50, representing year-over-year growth of 44%-54%.
What went well
- •Record royalty revenue of $236 million grew 52% year-over-year, lifting total revenue to $354 million, up 22% year-over-year.
- •Adjusted EBITDA grew 35% to $248.2 million, outpacing top-line growth and reflecting the leverage of the high-margin royalty-driven model.
- •Darzalex sales increased 20% on an operational basis to $3.7 billion, driven by share gains of about 5.7 percentage points across all lines of therapy and nearly 9 points in the front-line setting, marking the seventh consecutive quarter of front-line growth of five or more points.
- •Year to date, 13 of 15 growth catalysts were achieved, including Darzalex Subcutaneous European approval in smoldering multiple myeloma and VYVGART Hytrulo prefilled-syringe approval in Japan for self-injection.
- •The company announced the acquisition of Elektrofi, adding Hypercon technology that enables concentrations of 400-500 mg/ml and at-home autoinjector delivery for a broader range of biologics.
- •Year to date the company repurchased $342 million of shares and ended the quarter with $702 million in cash and a net debt-to-EBITDA ratio of 0.9x.
What went wrong
- •Collaboration revenues fell to $24 million from $48.4 million in the prior-year period, primarily due to the timing of milestones achieved.
- •The Elektrofi acquisition is expected to raise net leverage to roughly 2x net debt-to-EBITDA at closing and add approximately $55 million of incremental operating expense in 2026.
- •CFO Nicole LaBrosse will transition to a new opportunity in 2026, departing once a new CFO is hired or by March 30, 2026.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Total revenue | FY2025 | — | $1.3B-$1.375B (28%-35% YoY growth) | Raised |
| Royalty revenue | FY2025 | — | $850M-$880M (49%-54% YoY growth) | Raised |
| Product sales | FY2025 | — | $340M-$365M (12%-20% YoY growth) | Updated |
| Collaboration revenues | FY2025 | — | $110M-$130M | Updated |
| Adjusted EBITDA | FY2025 | — | $885M-$935M (40%-48% YoY growth) | Raised |
| Non-GAAP diluted EPS | FY2025 | — | $6.10-$6.50 (44%-54% YoY growth) | Raised |
| Elektrofi non-GAAP EPS dilution | Medium term | — | Less than 5% dilutive, excluding potential milestone payments | Reiterated |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Royalty revenue | +52% to $236M | Continued momentum of three blockbuster subcutaneous therapies: Darzalex Subcutaneous, Phesgo, and VYVGART Hytrulo. |
| Total revenue | +22% to $354.3M | Strong royalty growth, partially offset by lower collaboration revenue from milestone timing. |
| Adjusted EBITDA | +35% to $248.2M | Leverage of the high-margin royalty-driven model, outpacing top-line growth. |
| Product sales | +9% to $94.2M | Mainly driven by the contribution from proprietary product sales. |
| Collaboration revenues | -50% to $24M | Primarily due to the timing of milestones achieved. |
| Darzalex sales | +20% operational to $3.7B | Continued share gains across all lines of therapy and front-line setting, plus market growth. |
| R&D expenses | -6% to $17.3M | Lower compensation from resource optimization, offset by timing of ENHANZE high-yield rHuPH20 manufacturing investments. |
| SG&A expenses | +12% to $46.1M | Increased consulting and professional service fees, partially offset by lower compensation expense. |
| Non-GAAP diluted EPS | +35% to $1.72 | Strong royalty-driven revenue and EBITDA growth versus $1.27 in the prior-year quarter. |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| ENHANZE subcutaneous delivery momentum | — | Core driver of record royalty growth; 96% US and over 90% global subcutaneous share for Darzalex | rising |
| M&A and Elektrofi/Hypercon expansion | — | Acquired Elektrofi to add Hypercon at-home delivery; actively seeking further deals, willing to lever up to 3x net leverage | rising |
| New ENHANZE partnership deals | — | Confident in signing a new ENHANZE deal this year, with several discussions near completion | rising |
| Capital allocation and deleveraging | — | Balanced approach of buybacks and acquisitions; plan to delever quickly from ~2x at Elektrofi close | steady |
| Long-term royalty durability | — | Layered waves of royalty streams from blockbusters, recent launches, and pipeline extending into the 2030s and 2040s | rising |
Q&A summary
How do you weigh paying down debt versus buybacks and further Elektrofi-like deals, and how will investors monitor Elektrofi's performance?
Management continues to seek similar opportunities and will transact when appropriate. Robust cash flows will fund a modest credit-facility draw for Elektrofi and allow quick deleveraging while sustaining buybacks ($342 million year to date). Elektrofi progress can be tracked via two partner first-in-human starts of already-blockbuster products by end of 2026 or earlier, a streamlined development plan, and partners advancing more products or signing new deals.
What is partner awareness of Elektrofi's technology, and where is OCREVUS market growth coming from?
Awareness of Hypercon is good based on diligence, and partners working with both companies have signaled strong support, though the deal has not closed. On OCREVUS, Roche reported growth to roughly 12,500 patients with 50% new-to-brand in the US and Germany; management could not specify whether those are treatment-naive or switched patients, but views it as expanding the market footprint into physician offices and community settings.
How high are you willing to lever for M&A, and could another transaction come by year-end?
Another acquisition this year is unlikely as the focus is completing Elektrofi. The company is willing to go up to three times net leverage, expects about 2x at Elektrofi close coming down quickly, and will stay patient to find the right next opportunity in 2026.
When might feasibility studies on combining ENHANZE with Hypercon be conducted?
Combinability will be an early workstream between the technical teams, but the initial focus is pursuing each technology separately with its own pipeline of partner conversations: ENHANZE for high-volume rapid delivery and Hypercon/Elektrofi for at-home autoinjector delivery. The company does not need to wait for combination data.
What are the prospects for new near-term ENHANZE deals, and which products drove the guidance upside?
Management is confident of signing a new ENHANZE deal this year given several discussions near completion. The guidance upside is driven by strong royalties from VYVGART Hytrulo, Phesgo, and Darzalex, with VYVGART Hytrulo and Darzalex both benefiting from new indications launching this year whose first-year ramps came in ahead of expectations.
Do you currently have the partnerships needed to drive revenue into the next decade given Darzalex contract terminations in the early 2030s and five-year development timelines?
Management groups products into current blockbusters (Darzalex, VYVGART) with new indications driving growth into the 2040s, recently launched products (OCREVUS, Opdivo, Tecentriq, RYBREVANT) with royalties into the 2030s-2040s, and a phase 1-3 pipeline launching around or after 2028. New deals signed now could launch in the early 2030s, providing successive waves of new royalty revenue.